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Patients Characteristics
Age
Median (Range) 49 (18-68)
Sex
Male 20 (67%)
Female 10 (33%)
Disease Risk at HSCT
Lille
Low 6 (20%)
Intermediate 15 (50%)
High 9 (30%)
DIPPS
Low 2 (6%)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S285was done in all patients and 5 patients had 1-3 courses of DLI.
On follow up of the 43 patients with MC, 24 achieved com-
plete chimerism, 10 had stable mixed chimerism and 9 had
rejection (mostly level 3 MC). Two patients developed mild
graft versus host disease after DLI.
Conclusion: Occurrence of mixed chimerism is common
after allogeneic HSCT for thalassaemia after Fludarabine/
Treosulfan/Thiotepa conditioning. Rapid tapering of immu-
nosuppression and judicious use of DLI helps in reducing the
risk of secondary graft rejection. Closer monitoring of
chimerism after HSCT needs to be done when such condi-
tioning regimens are used.Intermediate-1 6 (20%)
Intermediate-2 17 (57%)
High 5 (17%)
JAK 2 Kinase
Positive 11 (37%)
Negative 11 (37%)
Unknown 8 (24)
Spleen
Enlarged 18 (60%)
Normal 4 (13%)
Removed 8 (27%)
Albumin 1
Median 3.9
Min 2.6
Max 4.9
LDH 2
Median 487
Min 126
Max 1304
ECOG
0 5
1 17
2 4
Unknown 4
1 Albumin normal value: 3.5-4.8 g/dl
2 LDH normal value: 98-192 IU/L406
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Introduction: Allogeneic stem cell transplantation (SCT) is
potentially curative for patients with Myeloﬁbrosis (MF).
However, treatment failure is common and often associated
with slow engraftment or graft failure, risk factors for which
are poorly deﬁned.
Patients: From 2000 to 2014, 30 adult patients (median
age, 49 (range 18-68) underwent SCT for primary or sec-
ondary MF at WCMC/NYP. All patients received PBSC from
matched related (MRD-14) or matched unrelated donors
(MUD-16). Most patients received ﬂudarabine and
melphalan (n¼22) conditioning. ATG or alemtuzumab were
used for patients who underwent MUD SCT. Only a mi-
nority of patients had low risk disease by DIPPS (26.7%) or
Lille (20%) risk scores. Twenty patients had splenomegaly, 6
by physical exam and 14 by imaging studies (median 24.5
Cm, range 16.2-34).
Results: After a median follow-up of 49.5 months (range 3 to
154 months), the 4-year OS and RFS are 44% (95%CI: 29%-
67%) and 37% (95%CI: 23%-61%) respectively. Neutrophil
engraftment by day 18 occurred in 63% of patients. Platelets
were engrafted by day 25 in 41% of patients. We used a Fine
and Gray’s proportional subdistribution hazard model.
Splenomegaly was associated with delayed neutrophil
engraftment (SHR¼0.42, 95% CI¼0.21, 0.83, p¼0.01), delayed
platelet engraftment (SHR¼0.18, 95%CI¼ 0.07, 0.48, p<0.001)
and non-relapse mortality (NRM) (SHR¼3.24, 95%CI¼0.94,
11.2, p¼0.06). Elevated LDH was associated with delayed
platelet engraftment (SHR¼0.39, 95% CI¼0.16, 0.94, p¼0.04)
and NRM (SHR¼2.82, 95%CI¼ 1.08, 7.35, p¼0.03). MUD
grafts were marginally associated with delayed neutrophil
engraftment (SHR¼0.55, 95% CI¼ 0.27, 1.12, p<0.10) but not
platelet engraftment or NRM.
Conclusion: Splenomegaly contributed to delayed neutro-
phil and platelet engraftment and NRM. Splenectomy should
be considered for patients with splenomegaly in need of
transplantation. Elevated LDH was associated with delayed
platelets engraftment and NRM and might indicate more
aggressive disease.407
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Objectives: To assess the effects of additional consolida-
tion therapy in acute myeloid leukemia (AML) patients
before allogeneic hematopoietic stem cell transplantation
(HSCT).
Methods: Seventy-two AML patients (range: 18-55 years)
who transplanted in CR1 after being treated with a standard
chemotherapy (7+3) regimen were randomly divided into
two groups. Thirty-six patients in group A directly under-
went transplantation and 36 in group B received chemo-
therapy regimen (5+2) prior to allogeneic HSCT. All patients
received fully HLA-matched transplants.
Results: Themedian age at transplantationwas 38.3 in group
A and 37.2 in group B. Themale to female ratio was 21:15 and
23:13 in groups A and B, respectively. The median time to
neutrophil and platelet recovery was 8 and 27 days in group
A, while it was 9 and 19 days in group B, respectively (P: 0.77,
0.01). Acute graft-versus-host disease (GvHD) was more
frequent in group A (26 vs. 23) patients(P:0.44). Chronic
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S286GvHD was more frequent in group A( 18 versus16)
patients(P: 0.37). Five relapses were observed in group A and
9 relapses occurred in group B (P: 0.23). The main causes of
death in both groups were relapse (50%) and aGvHD (22.2%).
The median follow-up time was 24 months. Diseaseefree
survival (DFS) was 47 in group A and 37 months (P: 0.34) in
groups B. The study showed overall survival (OS) of 45 and 34
months (P: 0.71) in groups A and B, respectively.
Conclusion: Even without considering the costs of treat-
ment, it is recommended that AML patients directly undergo
transplantation after being treated with a standard chemo-
therapy regimen (7+3) because no differences in DFS, OS,
GvHD were observed between the two groups.408
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Relapse is the most common cause of allogeneic stem cell
transplantation (SCT) failure. Non-cycling, chemoresistant
leukemic stem cells (LSCs) are thought to contribute to dis-
ease relapse and have been shown to be dependent on
signaling through the Hedgehog (Hh) pathway. Targeting
this pathway represents a rational approach to the eliminate
LSCs to prevent relapse. PF-04449913 (Pﬁzer) is a small
molecule inhibitor of the transmembrane G protein-coupled
Smoothened (SMO) receptor, a key mediator of the Hh
pathway. PF-04449913 demonstrates single-agent activity in
relapsed leukemias.
We designed an open label, Phase 2 study employing PF-
04449913 in acute leukemia andMDS patients following SCT.
Eligibility requirements include enrollment within 28-50
days of SCT, engraftment, and high risk of relapse. High
relapse risk is deﬁned for myeloablative conditioning regi-
mens in acute leukemia as the presence of persistent
morphologic disease or minimal residual disease (MRD) at
the time of transplant as measured by ﬂow cytometry, cy-
togenetics, or FISH, and, for MDS, persistent disease at the
time of transplant with poor risk cytogenetics. For non-
myeloablative transplants, patients with a relapse risk score
>0, as deﬁned by the Fred Hutchinson Cancer Research
Center scoring system, are also included. Patients receive
consecutive 28-day cycles of PF-04449913 at 100 mg/day for
up to one year or until toxicity or relapse. Twenty-eight pa-
tients are required for an 80% power to detect an estimatedFigure.one year relapse free survival improvement from a null hy-
pothesis of 30% to 53%.
To date 13 patients have enrolled including 9 AML, 3 ALL, and 1
MDS (7 myeloablative and 6 non-myeloablative). Median
follow up is 176 days. Three patients (one of whom relapsed)
required dose reductions to 50 mg due to muscle cramps and
dysgeusia, andonepatientdiscontinueddue tomuscle cramps.
No other signiﬁcant toxicities were attributed to the drug.
Three patients relapsed including one morphologic, one MRD,
and one with graft failure (developing prior to enrollment on
study)with subsequent relapse.Onepatient diedofGVHD, and
12 remain alive. One patient has completed the study and 7
remain on studywith amedianof 6 cycles completed (range 1-
10). Preliminary data suggests that PF-04449913 is well toler-
ated early post-SCT and may reduce relapse rates.409
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We recently found that early pre-emptiveDLI with
donor CD4+ T-Cells cultured in rapamycin (T-Rapa) allowed
allo-engraftment after low-intensity ﬂudarabine plus cyclo-
phosphamide (Cy) host conditioning (Blood, 2013). To eval-
uate further reductions in conditioning intensity, we
conducted a pilot clinical trial of allogeneic HSCT using a
novel regimen of pentostatin and low-dose, daily cyclo-
phosphamide (PC) in patients with refractory renal cell car-
cinoma (RCC, n¼10; Table 1). After PC conditioning, patients
received high dose sirolimus, a T-replete matched related
